Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Atripla to Eviplera for neurocognitive and emotional functioning in suppressed HIV
NL-OMON45204Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate and emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in neurocognitive composite score. Started Jul 2015; status: active, not recruiting.
02
Drugs
tenofovir disoproxil fumarateemtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON45204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45204.